According to Waters et al., HAR1A and HAR1B can act either as oncogenes or tumor suppressors in a cancer type-dependent manner, with their expression levels having potential as prognostic biomarkers, particularly in gliomas and oral carcinomas [53]. This evidence concerns the gene HAR1A and central nervous system cancer.